Table 3.
Agents | Clinical Phase | Identifier | Indication | Primary Endpoints |
---|---|---|---|---|
ARV-110 | I | NCT03888612 [115] | mCRPC | Dose-limiting toxicity, AE, PSA response |
AE: adverse event; mCRPC: metastatic castration-resistant prostate cancer; PSA: prostate-specific antigen.